FDA approves first twice-yearly injection that prevents HIV infection

The U S Food and Drug Administration FDA approved a new twice-yearly shot the first and only of its kind to prevent HIV the creator of the drug Gilead Sciences communicated on Wednesday Sold under the name Yeztugo the company s injectable HIV- capsid inhibitor lenacapavir reduces the exposure of sexually acquired HIV in adults and adolescents This is a historic day in the decades-long fight against HIV explained Daniel O Day chairman and CEO of California-based Gilead Sciences in a press release ALZHEIMER'S DISORDER COULD BE PREVENTED BY ANTIVIRAL DRUG ALREADY ON MARKETThe medicine which only necessities to be administered twice a year has shown remarkable outcomes in clinical studies as Gilead declares it could transform HIV prevention The drug is given as an injectable under the skin that the body then slowly absorbs Individuals must have a negative HIV- test prior to starting the cure In large trials last year the drug was not only nearly effective in its prevention of HIV but proved superior to once-daily oral medication like Truvada another drug by Gilead The journal Science named lenacapavir its Breakthrough of the Year CLICK HERE TO SIGN UP FOR OUR ROBUSTNESS NEWSLETTERLenacapavir uses a multi-stage approach that distinguishes it from other approved antiviral medications While majority antivirals act on just one stage of viral replication lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle states the press release from Gilead For more Wellbeing articles visit www foxnews com medical Yeztugo is one of the largest part significant scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic O Day declared in the press release The the greater part commonly announced adverse reactions during clinical trials included injection site reactions headache and nausea according to the company